Những tiến bộ gần đây trong liệu pháp y tế cho bệnh nhãn cầu Graves: Một tổng quan tài liệu toàn diện

Ponto KA et al (2015) Prevalence, Phenotype, and Psychosocial WellBeing in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy. Thyroid 5(8):942–948. https://doi.org/10.1089/thy.2015.0031 Perros P et al (2017) Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12(1):72. https://doi.org/10.1186/s13023-017-0625-1 Piantanida E et al (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36(6):444–449. https://doi.org/10.3275/8937 Smith TJ, Hegedüs L (2016) Graves’ Disease. N Engl J Med 375(16):1552–1565. https://doi.org/10.1056/NEJMra1510030 Ponto KA et al (2013) Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 98(1):145–152. https://doi.org/10.1210/jc.2012-3119 Dik WA, Virakul S, van Steensel L (2016) Current perspectives on the role of orbital fibroblasts in the pathogenesis of graves’ ophthalmopathy. Exp Eye Res 142:83–91. https://doi.org/10.1016/j.exer.2015.02.007 Krieger CC et al (2016) TSH/IGF-1 receptor cross talk in graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101(6):2340–2347. https://doi.org/10.1210/jc.2016-1315 Wang Y, Smith TJ (2014) Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 55(3):1735–1748. https://doi.org/10.1167/iovs.14-14002 Shadel GS, Horvath TL (2015) Mitochondrial ROS signaling in organismal homeostasis. Cell 163(3):560–569. https://doi.org/10.1016/j.cell.2015.10.001 Diana T et al (2018) Stimulatory TSH-receptor antibodies and oxidative stress in graves disease. J Clin Endocrinol Metab 103(10):3668–3677. https://doi.org/10.1210/jc.2018-00509 Van Regemorter E et al (2021) Downregulation of Caveolin-1 and upregulation of deiodinase 3, associated with hypoxia-inducible factor-1α increase, are involved in the oxidative stress of graves’ orbital adipocytes. Thyroid 31(4):627–637. https://doi.org/10.1089/thy.2020.0238 Hou TY et al (2021) The role of oxidative stress and therapeutic potential of antioxidants in graves’ ophthalmopathy. Biomedicines. https://doi.org/10.3390/biomedicines9121871 Lanzolla G, Marcocci C, Marinò M (2020) Oxidative Stress in Graves Disease and Graves Orbitopathy. Eur Thyroid J 9(Suppl 1):40–50. https://doi.org/10.1159/000509615 Du P, Ma X, Wang C (2014) Associations of CTLA4 gene polymorphisms with graves’ ophthalmopathy: a meta-analysis. Int J Genomics 2014:537969. https://doi.org/10.1155/2014/537969 Lahooti H et al (2015) Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves’ ophthalmopathy and Hashimoto’s thyroiditis. Clin Ophthalmol 9:1731–1740. https://doi.org/10.2147/opth.S87972 RotondoDottore G et al (2021) Genetic profiling of orbital fibroblasts from patients with graves’ orbitopathy. J Clin Endocrinol Metab 106(5):e2176–e2190. https://doi.org/10.1210/clinem/dgab035 Prummel MF et al (1990) Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 150(5):1098–1101 Karlsson F et al (1989) Ophthalmopathy and thyroid stimulation. Lancet 2(8664):691. https://doi.org/10.1016/s0140-6736(89)90945-8 Bartalena L et al (2021) The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. Eur J Endocrinol 185(4):G43–G67. https://doi.org/10.1530/eje-21-0479 George A et al (2020) Stimulatory thyrotropin receptor antibodies are a biomarker for graves’ orbitopathy. Front Endocrinol (Lausanne) 11:629925. https://doi.org/10.3389/fendo.2020.629925 Kampmann E et al (2015) Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study. Int J Endocrinol 2015:678194. https://doi.org/10.1155/2015/678194 Kahaly GJ et al (2019) High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with graves disease. J Clin Endocrinol Metab 104(7):2561–2568. https://doi.org/10.1210/jc.2018-02705 Fatourechi V (2012) Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab 26(4):553–565. https://doi.org/10.1016/j.beem.2011.10.001 Eckstein AK et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470. https://doi.org/10.1210/jc.2005-2813 Hägg E, Asplund K (1987) Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed) 295(6599):634–635. https://doi.org/10.1136/bmj.295.6599.634 Xing L et al (2015) Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy. Br J Ophthalmol 99(12):1686–1691. https://doi.org/10.1136/bjophthalmol-2014-306463 Tanda ML et al (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4):1443–1449. https://doi.org/10.1210/jc.2012-3873 Pfeilschifter J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45(4):477–481. https://doi.org/10.1046/j.1365-2265.1996.8220832.x Görtz GE et al (2016) Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in graves’ ophthalmopathy-implications for smoking. J Clin Endocrinol Metab 101(12):4834–4842. https://doi.org/10.1210/jc.2016-1279 Reiners C, Drozd V, Yamashita S (2020) Hypothyroidism after radiation exposure: brief narrative review. J Neural Transm (Vienna) 127(11):1455–1466. https://doi.org/10.1007/s00702-020-02260-5 Träisk F et al (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94(10):3700–3707. https://doi.org/10.1210/jc.2009-0747 Bartalena L et al (1998) Relation between therapy for hyperthyroidism and the course of graves’ ophthalmopathy. N Engl J Med 338(2):73–78. https://doi.org/10.1056/nejm199801083380201 Perros P et al (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves’ ophthalmopathy. J Clin Endocrinol Metab 90(9):5321–5323. https://doi.org/10.1210/jc.2005-0507 Sabini E et al (2018) High serum cholesterol is a novel risk factor for graves’ orbitopathy: results of a cross-sectional study. Thyroid 28(3):386–394. https://doi.org/10.1089/thy.2017.0430 Lanzolla G et al (2019) Cholesterol serum levels and use of statins in graves’ orbitopathy: a new starting point for the therapy. Front Endocrinol (Lausanne) 10:933. https://doi.org/10.3389/fendo.2019.00933 Lanzolla G et al (2018) Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. J Endocrinol Invest 41(12):1417–1423. https://doi.org/10.1007/s40618-018-0915-z Tall AR, Yvan-Charvet L (2015) Cholesterol, inflammation and innate immunity. Nat Rev Immunol 15(2):104–116. https://doi.org/10.1038/nri3793 Menconi F, Marcocci C, Marinò M (2014) Diagnosis and classification of Graves’ disease. Autoimmun Rev 13(4–5):398–402. https://doi.org/10.1016/j.autrev.2014.01.013 Blandford AD et al (2017) Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol 12(2):111–121. https://doi.org/10.1080/17469899.2017.1276444 Khazaei H et al (2021) The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves’ ophthalmopathy. Exp Eye Res 213:108813. https://doi.org/10.1016/j.exer.2021.108813 Aass C et al (2016) Comparative proteomic analysis of tear fluid in Graves’ disease with and without orbitopathy. Clin Endocrinol (Oxf) 85(5):805–812. https://doi.org/10.1111/cen.13122 Aass C et al (2017) Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy. PLoS ONE 12(4):e0175274. https://doi.org/10.1371/journal.pone.0175274 Kishazi E et al (2018) Thyroid-associated orbitopathy and tears: a proteomics study. J Proteomics 170:110–116. https://doi.org/10.1016/j.jprot.2017.09.001 Chng CL et al (2018) Tear proteins calcium binding protein A4 (S100A4) and prolactin induced protein (PIP) are potential biomarkers for thyroid eye disease. Sci Rep 8(1):16936. https://doi.org/10.1038/s41598-018-35096-x Oeverhaus M et al (2021) Graves’ orbitopathy: current concepts for medical treatment. Klin Monbl Augenheilkd 238(1):24–32. https://doi.org/10.1055/a-1328-2884 Werner SC (1969) Classification of the eye changes of Graves’ disease. Am J Ophthalmol 68(4):646–648. https://doi.org/10.1016/0002-9394(69)91246-x Werner SC (1977) Modification of the classification of the eye changes of graves’ disease: recommendations of the Ad Hoc committee of the American thyroid association. J Clin Endocrinol Metab 44(1):203–204. https://doi.org/10.1210/jcem-44-1-203 Dolman PJ, Rootman J (2006) VISA classification for graves orbitopathy. Ophthalmic Plast Reconstr Surg 22(5):319–324. https://doi.org/10.1097/01.iop.0000235499.34867.85 Bartalena L et al (2008) Consensus statement of the European group on graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285. https://doi.org/10.1530/eje-07-0666 Fayers T, Dolman PJ (2011) Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol 95(12):1670–1674. https://doi.org/10.1136/bjophthalmol-2011-300487 Vestergaard P (2002) Smoking and thyroid disorders–a meta-analysis. Eur J Endocrinol 146(2):153–161. https://doi.org/10.1530/eje.0.1460153 Kahaly GJ (2020) Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 105(12):3704–3720. https://doi.org/10.1210/clinem/dgaa646 RotondoDottore G et al (2017) Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy. Endocrine 58(2):386–389. https://doi.org/10.1007/s12020-016-1226-9 Xu B et al (2019) A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease. Turk J Med Sci 49(3):715–722. https://doi.org/10.3906/sag-1808-67 Marcocci C et al (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364(20):1920–1931. https://doi.org/10.1056/NEJMoa1012985 Negro R et al (2019) A 2018 European thyroid association survey on the use of selenium supplementation in graves’ hyperthyroidism and graves’ orbitopathy. Eur Thyroid J 8(1):7–15. https://doi.org/10.1159/000494837 Lanzolla G, Marinò M, Marcocci C (2020) Selenium in the treatment of graves’ hyperthyroidism and eye disease. Front Endocrinol (Lausanne) 11:608428. https://doi.org/10.3389/fendo.2020.608428 Lisi S et al (2011) Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest 34(7):521–527. https://doi.org/10.3275/7321 RotondoDottore G et al (2018) Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? J Endocrinol Invest 41(2):193–201. https://doi.org/10.1007/s40618-017-0718-7 RotondoDottore G et al (2018) Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO). J Endocrinol Invest 41(7):815–820. https://doi.org/10.1007/s40618-017-0809-5 CORTISONE in exophthalmos: report on a therapeutic trial of cortisone and corticotrophin (A.C.T.H.) in exophthalmos and exophthalmic ophthalmoplegia by a panel appointed by the Medical Research Council. Lancet, 1955. 268(6853):6–9 Marcocci C et al (2012) Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 166(2):247–253. https://doi.org/10.1530/eje-11-0779 Goldberg RA (2004) Orbital steroid injections. Br J Ophthalmol 88(11):1359–1360 Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320–332. https://doi.org/10.1210/jc.2010-1962 Stiebel-Kalish H et al (2009) Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 94(8):2708–2716. https://doi.org/10.1210/jc.2009-0376 Gao G et al (2014) Meta-analysis of methylprednisolone pulse therapy for Graves’ ophthalmopathy. Clin Exp Ophthalmol 42(8):769–777. https://doi.org/10.1111/ceo.12317 Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2–3):85–118. https://doi.org/10.1016/s0162-3109(00)00188-0 Ye X et al (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf) 86(2):247–255. https://doi.org/10.1111/cen.13170 Kahaly GJ et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6(4):287–298. https://doi.org/10.1016/s2213-8587(18)30020-2 Hassan AV, Sinha MD, Waller S (2013) A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome. Clin Kidney J 6(4):384–389. https://doi.org/10.1093/ckj/sft071 Arns W et al (2005) Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19(2):199–206. https://doi.org/10.1111/j.1399-0012.2004.00318.x Jia Y et al (2018) Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats. BMC Pharmacol Toxicol 19(1):39. https://doi.org/10.1186/s40360-018-0234-1 Prummel MF et al (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 321(20):1353–1359. https://doi.org/10.1056/nejm198911163212002 Kahaly G et al (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy a controlled, randomized and prospective study. Eur J Clin Invest 16(5):415–422. https://doi.org/10.1111/j.1365-2362.1986.tb01016.x Rajendram R et al (2018) Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6(4):299–309. https://doi.org/10.1016/s2213-8587(18)30021-4 Strianese D (2018) Efficacy and safety of immunosuppressive agents for thyroid eye disease. Ophthalmic Plast Reconstr Surg 34(4S Suppl 1):S56–S59. https://doi.org/10.1097/iop.0000000000001131 Chalvatzis NT et al (2014) Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. Eur J Ophthalmol 24(6):953–959. https://doi.org/10.5301/ejo.5000463 Shahida B et al (2019) Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves’ ophthalmopathy patients. Endocr Connect 8(9):1230–1239. https://doi.org/10.1530/ec-19-0319 Marinò M, Lanzolla G, Marcocci C (2021) Statins: a new hope on the horizon of graves orbitopathy? J Clin Endocrinol Metab 106(7):e2819–e2821. https://doi.org/10.1210/clinem/dgab184 Lanzolla G et al (2021) Statins for graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 9(11):733–742. https://doi.org/10.1016/s2213-8587(21)00238-2 Nilsson A, Tsoumani K, Planck T (2021) Statins decrease the risk of orbitopathy in newly diagnosed patients with graves disease. J Clin Endocrinol Metab 106(5):1325–1332. https://doi.org/10.1210/clinem/dgab070 Durrani OM, Reuser TQ, Murray PI (2005) Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 24(2):117–119. https://doi.org/10.1080/01676830590912562 Paridaens D et al (2005) The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) 19(12):1286–1289. https://doi.org/10.1038/sj.eye.6701768 van Steensel L et al (2011) Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves’ ophthalmopathy. Br J Ophthalmol 95(5):735–738. https://doi.org/10.1136/bjo.2010.192302 Ayabe R et al (2014) Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg 30(5):415–419. https://doi.org/10.1097/iop.0000000000000211 Salvi M et al (2007) Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33–40. https://doi.org/10.1530/eje.1.02325 El Fassi D et al (2009) Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130(3):252–258. https://doi.org/10.1016/j.clim.2008.09.007 Stan MN et al (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100(2):432–441. https://doi.org/10.1210/jc.2014-2572 Salvi M et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422–431. https://doi.org/10.1210/jc.2014-3014 Eid L et al (2020) The effects of rituximab on graves’orbitopathy: a retrospective study of 14 patients. Eur J Ophthalmol 30(5):1008–1013. https://doi.org/10.1177/1120672119845224 Ding C, Jones G (2003) Technology evaluation: MRA. Chugai Curr Opin Mol Ther 5(1):64–69 Pérez-Moreiras JV, Alvarez-López A, Gómez EC (2014) Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthalmic Plast Reconstr Surg 30(2):162–167. https://doi.org/10.1097/iop.0000000000000037 Perez-Moreiras JV et al (2018) Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181–190. https://doi.org/10.1016/j.ajo.2018.07.038 Copperman T et al (2019) Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg 35(3):e64–e66. https://doi.org/10.1097/iop.0000000000001346 Chen H et al (2015) TSH-Mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS ONE 10(6):e0130322. https://doi.org/10.1371/journal.pone.0130322 Chen H et al (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99(9):El635–El640. https://doi.org/10.1210/jc.2014-1580 Smith TJ et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748–1761. https://doi.org/10.1056/NEJMoa1614949 Douglas RS et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341–352. https://doi.org/10.1056/NEJMoa1910434 Bartalena L et al (2022) Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest 45(7):1455–1457. https://doi.org/10.1007/s40618-022-01791-w Inserro A (2021) The American Journal of Managed Care. Dr Rona Silkiss Details the Use of Biologics to Treat Thyroid Eye Disease. News release of the American Journal of Managed Care. https://www.ajmc.com/view/dr-paul-hahn-highlights-emerging-technologies-in-ophthalmology. Accessed Oct 07 2022 Kahaly GJ et al (2021) Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 9(6):360–372. https://doi.org/10.1016/s2213-8587(21)00056-5 Belinsky I et al (2022) Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg 38(1):73–78. https://doi.org/10.1097/iop.0000000000001995 Ding AS et al (2022) Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report. Otol Neurotol 43(2):e148–e152. https://doi.org/10.1097/mao.0000000000003428 Allen RC et al (2021) A perspective on the current role of teprotumumab in treatment of thyroid eye disease. Ophthalmology 128(8):1125–1128. https://doi.org/10.1016/j.ophtha.2021.03.006